Current developments in the diagnosis and treatment of giant cell arteritis
Giant cell arteritis is the most common vasculitis in adults above 50 years old. The disease is characterized by granulomatous inflammation of medium and large arteries, particularly the temporal artery, and is associated acutely with headache, claudication, and visual disturbances. Diagnosis of the...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.1066503/full |
| _version_ | 1811178276723359744 |
|---|---|
| author | Denes Szekeres Bayan Al Othman |
| author_facet | Denes Szekeres Bayan Al Othman |
| author_sort | Denes Szekeres |
| collection | DOAJ |
| description | Giant cell arteritis is the most common vasculitis in adults above 50 years old. The disease is characterized by granulomatous inflammation of medium and large arteries, particularly the temporal artery, and is associated acutely with headache, claudication, and visual disturbances. Diagnosis of the disease is often complicated by its protean presentation and lack of consistently reliable testing. The utility of color doppler ultrasound at the point-of-care and FDG-PET in longitudinal evaluation remain under continued investigation. Novel techniques for risk assessment with Halo scoring and stratification through axillary vessel ultrasound are becoming commonplace. Moreover, the recent introduction of the biologic tocilizumab marks a paradigm shift toward using glucocorticoid-sparing strategies as the primary treatment modality. Notwithstanding these developments, patients continue to have substantial rates of relapse and biologic agents have their own side effect profile. Trials are underway to answer questions about optimal diagnostic modality, regiment choice, and duration. |
| first_indexed | 2024-04-11T06:15:39Z |
| format | Article |
| id | doaj.art-c7ad7a8934964d97aaf7ea2bf2c380c7 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-11T06:15:39Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-c7ad7a8934964d97aaf7ea2bf2c380c72022-12-22T04:41:03ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-12-01910.3389/fmed.2022.10665031066503Current developments in the diagnosis and treatment of giant cell arteritisDenes Szekeres0Bayan Al Othman1School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, United StatesDepartment of Ophthalmology, University of Rochester Medical Center, Rochester, NY, United StatesGiant cell arteritis is the most common vasculitis in adults above 50 years old. The disease is characterized by granulomatous inflammation of medium and large arteries, particularly the temporal artery, and is associated acutely with headache, claudication, and visual disturbances. Diagnosis of the disease is often complicated by its protean presentation and lack of consistently reliable testing. The utility of color doppler ultrasound at the point-of-care and FDG-PET in longitudinal evaluation remain under continued investigation. Novel techniques for risk assessment with Halo scoring and stratification through axillary vessel ultrasound are becoming commonplace. Moreover, the recent introduction of the biologic tocilizumab marks a paradigm shift toward using glucocorticoid-sparing strategies as the primary treatment modality. Notwithstanding these developments, patients continue to have substantial rates of relapse and biologic agents have their own side effect profile. Trials are underway to answer questions about optimal diagnostic modality, regiment choice, and duration.https://www.frontiersin.org/articles/10.3389/fmed.2022.1066503/fullgiant cell (temporal) arteritiscolor Doppler ultrasonography (CDUS)biologic therapeuticsclinical trialsdiagnostics - clinical characteristics |
| spellingShingle | Denes Szekeres Bayan Al Othman Current developments in the diagnosis and treatment of giant cell arteritis Frontiers in Medicine giant cell (temporal) arteritis color Doppler ultrasonography (CDUS) biologic therapeutics clinical trials diagnostics - clinical characteristics |
| title | Current developments in the diagnosis and treatment of giant cell arteritis |
| title_full | Current developments in the diagnosis and treatment of giant cell arteritis |
| title_fullStr | Current developments in the diagnosis and treatment of giant cell arteritis |
| title_full_unstemmed | Current developments in the diagnosis and treatment of giant cell arteritis |
| title_short | Current developments in the diagnosis and treatment of giant cell arteritis |
| title_sort | current developments in the diagnosis and treatment of giant cell arteritis |
| topic | giant cell (temporal) arteritis color Doppler ultrasonography (CDUS) biologic therapeutics clinical trials diagnostics - clinical characteristics |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.1066503/full |
| work_keys_str_mv | AT denesszekeres currentdevelopmentsinthediagnosisandtreatmentofgiantcellarteritis AT bayanalothman currentdevelopmentsinthediagnosisandtreatmentofgiantcellarteritis |